Latham & Watkins Advises Eagle Pharmaceuticals in Royalty Monetization With Blue Owl Capital

Eagle Pharmaceuticals, Inc. (OTCMKTS: EGRX) (Eagle) has announced that it has entered into a royalty monetization transaction with Blue Owl Capital Inc. (Blue Owl), dated March 31, 2025, to sell the royalty interest in annual net sales of BENDEKA® (bendamustine hydrochloride injection) in the United States for an aggregate purchase price of US$69 million before transaction costs. Funds managed by Blue Owl provided capital for the transaction.

Latham & Watkins LLP represents Eagle Pharmaceuticals in the transaction with a transactional team led by Bay Area partners Haim Zaltzman and Dan Van Fleet, with associates Axel Magnusson and Ian Drazen. Advice was also provided on securitization matters by Chicago partner Matt Hays and New York partner Suzzanne Uhland and Orange County counsel Josh Strathman, with associate Shirley Zhang;* on tax matters by Los Angeles partner Eric Cho, with associate Jeremiah Cowen; and on IP and licensing matters by Chicago partner Alex Grabowski and Washington, D.C./New York partner Daniel Brown and New York counsel Eliot Choy, with associate Patrick Chew.

*Admitted to practice in New South Wales (Australia) only.